Abstract 305P
Background
The prognosis in patients with breast cancer with isolated locoregional recurrence (ILRR) without simultaneous distant metastases after immediate breast reconstruction (IBR) remains unknown. We aimed to investigate the prognosis in this patient population.
Methods
This multi-institutional retrospective observational study evaluated 3,295 patients with primary breast cancer who underwent IBR at 12 Japanese medical facilities between January 1, 2008 and December 31, 2016. The outcome measures were the prognostic factors for ILRR after IBR, 5-year distant metastasis-free survival (DMFS), and 5-year overall survival (OS).
Results
Mastectomy or skin-sparing mastectomy was performed in 3,295 patients. ILRR occurred in 70 patients, and the median observation period from ILRR diagnosis was 39.3 months. Of the 70 patients, 9 (12.9%) had axillary lymph node recurrence (ALNR) at the time of ILRR diagnosis. The 5-year DMFS after ILRR was 92.4%. Patients with ILRR who had ALNR had a significantly worse DMFS than that had by those without ALNR (P = 0.005).The 5-year OS after ILRR was 91.2%. Patients with ILRR who had ALNR had a significantly worse OS than that had by those without ALNR (P = 0.005).The relationship between DMFS and clinicopathological factors was analyzed using the Cox proportional hazards model. Univariate analysis revealed significant associations of pN at primary surgery (P = 0.041) and ALNR at ILRR (HR: 9.960, 95% CI: 1.400–70.862, P = 0.022) with DMFS. However, ALNR was the only independent prognostic factor for DMFS in the multivariate analysis (P = 0.041). Univariate analysis revealed significant associations of post-mastectomy radiation therapy (PMRT) at primary surgery (P = 0.023) and ALNR at ILRR (P = 0.043) with OS. In multivariate analysis, both PMRT (P = 0.010) and ALNR (P = 0.028) were independent prognostic factors for OS.
Conclusions
Although patients with breast cancer who have ILRR after IBR have a favorable prognosis overall, ALNR at the diagnosis of ILRR may be a poor prognostic factor. Our results may contribute to developing strategies to predict prognosis in patients with breast cancer who develop ILRR after IBR.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Collaborative Study Group of Scientific Research of the Japanese Breast Cancer Society.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
281P - Prevalence of HER2-low breast cancer in the GEICAM/2011-06 trial: Agreement in HER2-low classification between standardized immunohistochemistry assays
Presenter: Federico Rojo
Session: Poster session 14
282P - Impact of pembrolizumab on ovarian function in young triple negative breast cancer patients treated with chemo-immunotherapy
Presenter: Anne Perdrix
Session: Poster session 14
283P - Immune-mediated secondary adrenal insufficiency is more commonly found in younger patients undergoing neoadjuvant treatment for early breast cancer
Presenter: Laura Lapuchesky
Session: Poster session 14
284P - Clinical and molecular characteristics of early-stage triple-negative breast cancer (eTNBC) patients with germline pathogenic variants in homologous recombination repair genes
Presenter: Adela Rodriguez Hernandez
Session: Poster session 14
285P - Adherence to endocrine therapy and sexual dysfunction in patients older than 65 years with early estrogen receptor-positive breast cancer
Presenter: Daniele Assad
Session: Poster session 14
286P - Impact of adjuvant endocrine therapy on survival outcomes in female breast cancer patients over 50
Presenter: Hanxiao Zuo
Session: Poster session 14
287P - Cognitive impairment in older breast cancer survivors
Presenter: Sharon Giordano
Session: Poster session 14
289P - Low risk febrile neutropenia: Does combined chemotherapy/immune checkpoint inhibitor necessitate a change in approach?
Presenter: Jamie Weaver
Session: Poster session 14
290P - Subtype-specific prognostic value of lobular histology in patients with early-stage breast cancer: A nationwide population-based study
Presenter: Guilherme Nader Marta
Session: Poster session 14